Hansa Biopharma (HNSB.F) Stock Overview
A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
HNSB.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Hansa Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.70 |
| 52 Week High | SEK 4.58 |
| 52 Week Low | SEK 2.90 |
| Beta | 1.6 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 23.33% |
| 3 Year Change | -5.85% |
| 5 Year Change | n/a |
| Change since IPO | -19.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| HNSB.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -4.4% | -0.2% |
| 1Y | 23.3% | 39.9% | 14.8% |
Return vs Industry: HNSB.F underperformed the US Biotechs industry which returned 39.9% over the past year.
Return vs Market: HNSB.F exceeded the US Market which returned 14.8% over the past year.
Price Volatility
| HNSB.F volatility | |
|---|---|
| HNSB.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: HNSB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine HNSB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 131 | Renee Aguiar-Lucander | www.hansabiopharma.com |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.
Hansa Biopharma AB (publ) Fundamentals Summary
| HNSB.F fundamental statistics | |
|---|---|
| Market cap | US$461.52m |
| Earnings (TTM) | -US$78.55m |
| Revenue (TTM) | US$19.71m |
Is HNSB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNSB.F income statement (TTM) | |
|---|---|
| Revenue | SEK 189.46m |
| Cost of Revenue | SEK 81.14m |
| Gross Profit | SEK 108.32m |
| Other Expenses | SEK 863.47m |
| Earnings | -SEK 755.14m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 05, 2026
| Earnings per share (EPS) | -7.42 |
| Gross Margin | 57.17% |
| Net Profit Margin | -398.58% |
| Debt/Equity Ratio | -197.5% |
How did HNSB.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 18:13 |
| End of Day Share Price | 2026/07/30 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hansa Biopharma AB (publ) is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Christian Lee | ABG Sundal Collier Sponsored |
| Madhu Kumar | B. Riley Securities, Inc. |